05:39 AM EDT, 07/10/2025 (MT Newswires) -- Klotho Neurosciences ( KLTO ) said Thursday the US Food and Drug Administration has granted orphan drug designation to KLTO-202, which is intended for the treatment of amyotrophic lateral sclerosis.

The designation provides incentives such as tax credits, fee waivers and extended US market exclusivity.

Klotho Neurosciences ( KLTO ) said it will have completed studies in two animal models of human ALS and is currently initiating manufacturing of the product, which will be followed by meetings with US and European regulators to agree on a development path.

ALS is a debilitating neurodegenerative disease leading to paralysis with a life expectancy of two to five years following diagnosis.

Shares of Klotho were up more than 40% in recent premarket activity.

Price: 1.93, Change: +0.56, Percent Change: +40.88